Abstract. Liver X receptors (LXRs) exert anti-inflammatory effects in animal models of certain respiratory diseases. In the present study, a model of chronic airway remodeling was established in wild-type and LXR-deficient mice. Ovalbumin (OVA)-sensitized mice were chronically administered OVA via inhalation for 8 weeks. Prior to each stimulation, certain wild-type mice were treated with GW3965, which is a highly selective LXR agonist. The influence of LXRs on airway inflammation, airway hyperresponsiveness and airway remodeling was evaluated. LXRs were indicated to increase airway inflammation and airway hyperresponsiveness, as well as promote airway remodeling. These results suggest that inhibiting LXRs may be a potential method for the treatment of allergic asthma.

Introduction

Asthma is a highly prevalent chronic airway disease, which affects >300 million individuals worldwide (1). Its morbidity and mortality rate are increasing gradually with the development of the society. The symptoms include shortness of breath, cough and chest tightness (2). To date, the pathological mechanisms of asthma have remained to be fully elucidated. Studies have indicated that the disease is an inflammatory disorder of the conducting airways, which has a strong association with allergic sensitization (3). It is classically recognized as a typical type 2 T-helper cell (Th2) disease, with increased immunoglobulin E (IgE) levels and eosinophilic inflammation in the airways. Resulting from airway inflammation, airway remodeling leads to airway wall thickening and induces increased airway smooth muscle mass, which generates asthmatic symptoms (4). Chronic airway inflammation, airway hyperresponsiveness and airway remodeling are the central pathogenic processes of this disease (5).

Liver X receptors (LXRs) belong to the nuclear receptor superfamily and occur in two forms, known as LXRα and LXRβ (6). Previous studies have established LXRs as the key modulators of both lipid metabolism and inflammation (7-10). When combined with natural ligands, such as oxysterols or desmosterol (11), or synthetic ligands, including GW3965 or T0901317 (12), LXRs regulate the transcription of genes involved in cholesterol efflux and macrophage-mediated inflammation. The LXR ligand exerts inhibitory roles in lipopolysaccharide-induced lung inflammatory responses and anti-proliferative effects on airway smooth muscle (13-16). However, LXRs fail to attenuate acute allergic airway inflammation and Th2 cytokines in bronchoalveolar lavage fluid (BALF) (17). In chronic allergic asthma, LXRs have the ability to reduce serum IgE. Furthermore, the LXR agonist T0901317 is able to inhibit the airway remodeling process (12,18,19). However, T0901317 is not highly selective for LXRs and it is also able to activate other nuclear receptors, such as the Farnesoid X receptor (20,21). To the best of our knowledge, there are currently no data regarding chronic allergic asthma in LXR-deficient mice. Therefore, the present study used LXR-deficient mice and a highly selective agonist of LXRs to investigate the role of LXRs in allergen-induced chronic asthma.

Materials and methods

Mice and ethics statement. A total of 36C57BL/6 female mice (age, 8 weeks; weight, 19±2g) were obtained from the Mice Breeding Service Department of GemPharmatech. Animals were given free access to sterilized tap water and a standard rodent chow in a specific pathogen-free biosafety level 3 facility at a temperature of 22-24°C and a relative humidity of 50-60%. An artificial 12 h light/dark cycle with suitable ventilation was maintained in the animal room.

The present experiment was approved by The Institutional Animal Care and Use Committee of Nanjing First Hospital Affiliated to Nanjing Medical University Animal Center.
(Nanjing, China). Animal experiments were performed in strict accordance with the provisions of the Guidance on Feeding and Use of Experimental Animals by the Ministry of Science and Technology of the P.R. China. All operations were performed under anesthesia and all efforts were made to minimize suffering.

Establishment of the mouse model and drug intervention. Mice were randomly divided into six groups (n=6 mice/group) as follows: Control group, ovalbumin (OVA) group, GW3965 group, LXRα−/− group, LXRβ−/− group and LXRαβ knockout (KO) group. Certain wild-type mice received intervention with the LXR agonist GW3965 (Cayman Chemical Company) at 20 mg/kg by intraperitoneal injection. LXR-KO mice and wild-type mice were used to establish a chronic asthma model (18). Mice were intraperitoneally injected with 0.1 ml sensitizing solution [0.1 mg OVA; 0.07 ml Imject™ Alum Adjuvant (Beijing Biolead Biotechnology Co., Ltd.); 0.03 ml PBS] on days 0, 7 and 14. The mice were stimulated with 1% OVA solution using an ultrasonic nebulizer (402AI; Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.) from day 21 for 30 min each time, three times a week, for 8 consecutive weeks. Mice treated with the LXR agonist were administered an intraperitoneal injection of GW3965 at 20 mg/kg (10.22) prior to each stimulation.

Airway physiology. Airway responsiveness was measured 24 h after the last OVA treatment using an AniRes 2005 Lung Function system (Bestlab). The mice were anesthetized with Nembutal (60 mg/kg; intraperitoneal). The trachea was then surgically exposed and connected to a computer-controlled ventilator using an intratracheal tube. The respiration rate and the expiratory/inspiratory time ratio were measured at base line and after increasing concentrations, with intervals of 5 min from 10 to 200 µg/kg. The values of airway resistance were recorded by the system after the administration of acetylcholine (1:50 dilution, cat. no. GA085; Dako; Agilent Technologies, Inc.) was added and the slices were incubated for 2 h at 37˚C or overnight at 4˚C. Following rinsing three times with PBS for 5 min, these slices were blocked with 5% normal goat serum [Hangzhou Multisciences (Lianke Biotech, Co., Ltd.) in PBS at room temperature for 10 min to eliminate the activity of endogenous peroxidase. Subsequently, the slices were rinsed with distilled water and soaked twice in PBS for 5 min. Then, the slices were incubated with 1:50 dilution; cat. no. GA085; Dako; Agilent Technologies, Inc.) was added and the slices were incubated for 2 h at 37˚C or overnight at 4˚C. Following rinsing three times with PBS for 5 min, the peroxidase-labeled goat anti-mouse polyclonal IgG antibody (1:1,000 dilution; cat. no. AP124ASigma-Aldrich; Merck KGaA) was added and the slices were incubated at 37˚C for 30 min. This was followed by rinsing with PBS and staining with diamobenzidine at -20˚C for 5 min. (Santa Cruz Biotechnology, Inc.). After washing, re-dyeing with hematoxylin at 37˚C for 5 min and dehydration, the slides were made transparent and sealed with neutral gum. Image Pro Plus 6.0 software (Media Cybernetics, Inc.) was used for analysis of the immunostained sections. Results were presented as the area of a-SMA immunostaining per µm length of the basement membrane of the bronchioles that had a 150-200 µm internal diameter. In total, ≥10 bronchioles were randomly selected in each of the slides.

Statistical analysis. Values are expressed as the mean ± standard error of the mean. Comparisons among the different groups were performed by one-way ANOVA (with nonparametric or mixed test) followed by Tukey’s post-hoc test for multiple comparisons (GraphPad Prism 8.0). Statistical comparisons used SPSS 16.0 (SPSS, Inc.). P<0.05 was considered to indicate statistical significance.
Results

LXRs increase airway hyperresponsiveness in the chronic model of asthma. After the administration of the indicated doses of aerosolized acetylcholine for 20 sec, at 24 h after the last OVA challenge, lung resistance (RL) was recorded (Fig. 1). There was no difference in basic airway resistance between the groups. Administration of acetylcholine induced a concentration-dependent increase in RL in each group. When the stimulation dose reached 200 µg/kg, the airway resistance was higher in the GW3965 group compared with that in the OVA group (P<0.05). Furthermore, the airway resistance was lower in the LXRα/β KO group compared with that in the OVA group (P<0.05). However, there was no decrease in the RL of LXRα−/− mice and LXRβ−/− mice compared with that in the mice in the OVA group (data not shown).

Effect of LXRs on lung histology in the chronic model of asthma. Rare inflammatory cells were observed around the airways in the control group. Furthermore, mice in the OVA group presented with severe infiltration of inflammatory cells around the respiratory tract and mice in the GW3965 group presented with a marked increase in inflammatory cells around the airways. In addition, LXRα− mice and LXRβ− mice did not exhibit any reduced OVA-induced inflammation of the airways. It was indicated that LXRα/β KO mice presented with reduced inflammation of the airways compared with mice in the OVA group (Fig. 2A-F).

Effect of LXRs on inflammatory cells in the BALF of the chronic model of asthma. Following sensitization and treatment challenges, the total number of leukocytes, as well as macrophages, eosinophils, lymphocytes and neutrophils in the BALF of the OVA group were significantly increased compared with those in the control group. It was indicated that treatment with GW3965 significantly enhanced the number of eosinophils and lymphocytes in the BALF compared with those in the OVA group. Furthermore, LXRα/β KO mice had fewer total leukocytes, macrophages, lymphocytes and eosinophils as compared with mice in the OVA group. However, there was no significant depression of inflammatory cells in the BALF of LXRα−/− mice and LXRβ−/− mice compared with those in the OVA group (Fig. 3).

Effect of LXRs on IL-4, IL-5 and IL-13 levels in the BALF and IgE levels in serum of the chronic model of asthma. The levels of IL-4, IL-5 and IL-13 in the BALF were significantly higher in the OVA group compared with those in the control group. Furthermore, the levels of the inflammatory cytokines were higher in the GW3965 group compared with those in the OVA group. However, the levels of these inflammatory cytokines were lower in the LXRα/β KO group compared with those in the OVA group. Compared with the control group, the OVA, GW3965 and LXRα/β KO groups had significantly higher IgE levels. The IgE levels in the LXRα/β KO group were significantly higher compared with those in the OVA group, while the GW3965 group had significantly lower levels (Fig. 4A-D).

LXRs inhibit airway remodeling in chronic experimental asthma. The level of airway metaplasia and mucus production was assessed via PAS staining of lung tissues (Fig. 5A-G). There was a low number of PAS-positive goblet cells in the control...
Figure 2. LXR-deficient, chronic asthmatic mice display reduced airway inflammation. After the last OVA challenge, lung tissues were fixed, sectioned and stained with H&E. The inflammatory cells around the airways and vessels were observed by pathologists (red arrows). Representative images for the (A) Control group, (B) OVA group, (C) GW3965 group, (D) LXRα−/− group, (E) LXRβ−/− group and (F) LXRαβ KO group (magnification, x200). LXR, liver X receptor; OVA, ovalbumin; KO, knockout.

Figure 3. LXR-deficient, chronic asthmatic mice have a reduced number of inflammatory cells in the BALF. Cells were isolated via centrifugation from the BALF and were subjected to Wright-Giemsa staining. Cell numbers and cell differentiation were determined using a hemocytometer (≥200 cells were counted). *P<0.05 OVA group vs. control group; †P<0.05 GW3965 group vs. OVA group; ‡P<0.05 LXR-deficient groups vs. OVA group. LXR, liver X receptor; OVA, ovalbumin; BALF, bronchoalveolar lavage fluid; KO, knockout; GW, GW3965 group.
group, while the number of PAS-positive goblet cells was markedly increased in the OVA group and further increased in the GW3965 group. In addition, the number of PAS-positive goblet cells was significantly lower in the LXRα/β KO group compared with that in the OVA group.

The effect of the LXR agonist GW3965 on the area of collagen deposition around the duct wall was determined using Masson’s trichrome staining analysis of lung tissues (Fig. 6A-G). In the control group, collagen deposition around the airways was minimal. The results demonstrated that the collagen deposition around the airways of mice in the OVA group was significantly increased compared with that in the control group (P<0.05). In addition, compared with that in the OVA group, the collagen deposition area was increased in the GW3965 group (P<0.05), while this area was decreased in the LXRα/β KO group (P<0.05).

The results further demonstrated that α-SMA expression was increased in the peribronchiolar region of OVA-challenged mice compared with that in control mice. In addition, administration of GW3965 markedly increased the area of the α-SMA-stained smooth muscle layer compared with that in the OVA group. However, the area of smooth muscle layer stained with α-SMA was reduced in the LXRα/β KO group as compared with that in the OVA group (Fig. 7A-G). These results indicated that LXRs may promote airway remodeling.

Discussion

The present study investigated the effect of LXRs on the pathophysiology of asthma by establishing an LXR-deficient mouse model of chronic allergic asthma. The influence of LXRs on the pathophysiological process of chronic asthma was comprehensively evaluated by detecting airway inflammation, airway hyperreactivity and airway remodeling.

The synthetic agonist used in the present study was GW3965, which is a highly LXR-specific ligand. GW3965 increased the eosinophilic airway inflammation by inducing high secretory levels of Th2 cytokines. A previous study reported that LXR activation is able to directly increase the transcription of IL-5 by improving the promoter activity (23). However, to the best
of our knowledge, there are no previous studies suggesting that LXRα and LXRβ are able to increase the transcription of IL-4 and IL-13. The present study demonstrated that activation of LXR led to the production of IL-4 and IL-13 in the airways of model mice with chronic asthma. These results indicated that LXRs may affect T-cell function by increasing the Th2 cytokine response.
An important feature of allergic asthma is the increase in IgE levels in the serum. IgE-mediated type I allergy is the primary mechanism of the asthma response and leads to airway hyperresponsiveness (24), particularly when asthmatic patients are exposed to allergens. Allergens are captured by antigen-presenting cells and are presented to T lymphocytes, which is a process that requires a suitable Th2 cytokine environment to enable the B-cell type conversion to a type that produces IgE (25-27).

Both IL-4 and IL-13 are able to transpose the mRNA of B cells, thereby caus ing the transformation of B cells and the production of IgG4 and IgE with the appropriate co-stimulus signals. The production of IgE is largely dependent on T-cell synthesis, while basophils and mast cells are able to express CD40 ligand (CD40L), interact with B cells and regulate IgE synthesis in the absence of endogenous IL-4 and IL-13 (28). Therefore, basophils and mast cells are able to induce IgE syngenesis without T cells, which is another important pathway for IgE synthesis (29-31). It has been indicated that LXR activation limits anti-CD40 and IL-4-induced differentiation of B cells into IgE-secreting plasmablasts and this may be associated with the reduced phosphorylation of JNK and the increased membrane expression of CD23 (25). In the present study, an appropriate dose of LXR agonist was able to effectively reduce serum IgE levels. On the basis that binding to LXR agonists increased Th2 cytokines, it was suggested that LXR agonists may inhibit IgE production by inhibiting the non-T-cell-dependent pathways and this observation was in line with previous studies (18,32).

Acetylcholine is a type of drug that causes bronchoconstriction and increases airway resistance when inhaled. The present study used different doses of acetylcholine to stimulate the airways. The results demonstrated that LXRs were able to increase airway hyperreactivity. This finding maybe explained by the increase in airway inflammation caused by LXRs.

The specific manifestations of airway remodeling include epithelial injury, hypertrophy of subepithelial fibrous mucous glands, myofibroblast, smooth muscle cell proliferation and angiogenesis (33). In the present study, when comparing the LXR agonist group with the asthma group, the aforementioned changes were more obvious. It was identified that airway remodeling was decreased in LXRα/β KO mice, which indicated that LXRs promote airway remodeling during chronic asthma. While LXRs were previously indicated to exert anti-proliferative effects on airway smooth muscle in vitro (16), the role of LXRs in mice with chronic asthma appeared to be more complex.

LXRs serve a key role in lipid metabolism and exhibit anti-inflammatory roles in a number of animal models, including those of atherosclerosis and acute lung injury (34). In the present study, it was observed that LXRs aggravated antigen-induced eosinophilic airway inflammation in mice with chronic asthma. However, asthma is a heterogeneous disease with multiple phenotypes (1), and there are numerous non-allergic asthmatic patients with neutrophilic airway inflammation (1,35). It is suggested that LXRs may have favorable inhibitory effects on airway inflammation in non-allergic asthma; however, further research is required.

In conclusion, the present study demonstrated that LXRs promote airway remodeling in allergic chronic asthma and this may be a promising target for allergic asthma treatment. Inhibition of LXR overactivation may reduce allergic airway inflammation and airway hyperresponsiveness, as well as...
decrease airway remodeling. Therefore, inhibiting LXRbs may be a potential treatment for allergic asthma.

Acknowledgements

Not applicable.

Funding

The study was supported by the Nanjing Medical Science and Technique Development Foundation (grant no. JQX16028).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YS, LY and WG designed the experiments. JZ, ZW and FY performed the experiments. JZ, ZW and FY analyzed data and performed immunohistochemistry. JZ and YT checked and approved the authenticity of all the raw data. The manuscript was written by JZ and YS. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present experiment was approved by The Institutional Animal Care and Use Committee of Nanjing First Hospital Affiliated to Nanjing Medical University Animal Center.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Boonpiyathad T, Sözener ZC, Satikutsanapoo P and Akdis CA: Immuneologic mechanisms in asthma. Semin Immunol 40: 101333, 2019.
2. Insuelo DBR, Ferraoro MR, Coutinho DS, Martins MA and Carvalho VF: Could arachidonic acid-derived pro-resolving mediators be a new therapeutic strategy for asthma therapy? Front Immunol 11: 580-598, 2020.
3. Holgate ST, Arshad HS, Roberts GC, Howarth PH, Thurner P and Davies DE: A new look at the pathogenesis of asthma. Clin Sci (Lond) 118: 439-450, 2009.
4. Kado M, Ishigatsubo Y and Aoki I: Pathology of asthma. Front Microbiol 4: 263, 2013.
5. Russell RJ and Brightling C: Pathogenesis of asthma: Implications for precision medicine. Clin Sci (Lond) 131: 1723-1735, 2017.
6. Birrell MA, De Alba J, Catley MC, Hardaker E, Wong S, Collins M, Clarke DL, Farrow SN, Willson TM, Collins JL and Belvisi MG: Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J Immunol 181: 4265-4271, 2008.
7. Castrillo A and Tontonoz P: Nuclear receptors in macrophage biology: At the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 20: 455-480, 2004.
8. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ and Tontonoz P: Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9: 213-219, 2003.
9. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ and Tontonoz P: Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 278: 10443-10449, 2003.
10. Smet M, Van Hoecke L, De Beuckelaer A, VanderBeken S, Naessens T, Vergote K, Willart M, Lambrecht BN, Gustafsson JA, Stevens KR and Grooten J: Cholesterol-sensing liver X receptors stimulate TH2-driven allergic eosinophilic asthma in mice. Immun Inflamn Dis 4: 350-361, 2016.
11. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K., et al: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112: 1318-1331, 2003.
12. Ogawa D, Stone JF, Takata Y, Blaschke F, Chiu VH, Towler DA, Law RE, Hsueh WA and Bruemmer D: Liver X receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res 96: e59-e67, 2005.
13. Solan PD, Piraino G, Hake PW, Denenberg A, O’Connor M, Lentsch A and Zingarelli B: Liver X receptor activation with the synthetic ligand T0901317 reduces lung injury and inflammation after hemorrhage and resuscitation via inhibition of the nuclear factor κB pathway. Shock 35: 367-374, 2011.
14. Wang D, Liu M, Wang Y, Luo M, Wang J, Dai C, Yan P, Zhang X, Wang Y, Tang C and Xiao J: Synthetic LXR agonist T0901317 attenuates lipopolysaccharide-induced acute lung injury in rats. Int Immunopharmacol 11: 2098-2103, 2011.
15. August A, Mueller C, Weaver V, Polanco TA, Walsh ER and Cantorna MT: Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma. J Nutr 136: 695-699, 2006.
16. Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Choi OH, Kim JS, Lee MK and Lee YC: PPAR-gamma modulates allergic inflammation through up-regulation of PTEN, FASEB J 19: 1033-1035, 2005.
17. Zelcer N and Tontonoz P: Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614, 2006.
18. Shi Y, Xu X, Tan Y, Mao S, Fang S and Gu W: A liver-X-receptor ligand, T0901317, attenuates IgE production and airway remodeling in chronic asthma model of mice. PLoS One 9: e92668, 2014.
19. Ogawa S, Lozaeh J, Benner C, Paschul G, Tangirala RK, Westen S, Hoffmann A, Subramaniam S, David M, Rosenfeld MG and Glass CK: Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122: 707-721, 2005.
20. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ and Tontonoz P: Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 278: 10443-10449, 2003.
21. Michael LF, Schkeryantz JM and Burris TP: The pharmacology of LXR. Mini Rev Med Chem 5: 729-740, 2005.
22. Zhao Z, Xu D, Li S, He B, Huang Y, Xu M, Ren S, Li S, Wang H and Xie W: Activation of liver X receptor attenuates oleic acid-induced acute respiratory distress syndrome. Am J Pathol 186: 2614-2622, 2016.
23. Chen Y, Duan K, Yang Y, Yang X, Jiang M, Zhang L, Li G, Yin Z, Hu W, Dong P, et al: Activation of liver X receptor induces macrophage interleukin-5 expression. J Biol Chem 287: 34330-34350, 2012.
24. Asayama K, Kobayashi T, D’Alessandro-Gabazza CN, Toda M, Yasuma T, Fujimoto H, Okano T, Saiki H, Takeshita A, Kotsuka K, et al: Protein S protects against allergic bronchial asthma by modulating TLR2/β2 signaling. Allergy 75: 2267-2278, 2020.
25. Heine G, Dahlen A, Hilt K, Ernst D, Milovanovic M, Hartmann B and Worm M: Liver X receptors control IgE expression in B cells. J Immunol 182: 5276-5282, 2009.
26. Nunomura S, Endo K, Makishima M and Ra C: Oxysterol represses high-affinity IgE receptor-stimulated mast cell activation in Liver X receptor-dependent and -independent manners. FEBS Lett 584: 1143-1148, 2010.
27. Gould HJ and Sutton BF: IgE in allergy and asthma today. Nat Rev Immunol 8: 205-217, 2008.
28. Jabara HH, Fu SM, Gehr RS and Vercelli D: CD40 and IgE: Synergy between anti-CD40 monoclonal antibody and inter-leukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 172: 1861-1864, 1990.
29. Lala DS: The liver X receptors. Curr Opin Investig 6: 934-943, 2005.
30. Tontonoz P and Mangelsdorf DJ: Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17: 985-993, 2003.
31. Chen S, Sims GP, Chen XX, Gu YY, Chen S and Lipsky PE: Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179: 1634-1647, 2007.
32. Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM and Holleran WM: Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol 125: 160-169.e1-e5, 2010.
33. Delvecchio CJ, Bilan P, Radford K, Stephen J, Trigatti BL, Cox G, Parameswaran K and Capone JP: Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol Endocrinol 21: 1324-1334, 2007.
34. Zhao L, Lei W, Deng C, Wu Z, Sun M, Jin Z, Song Y, Yang Z, Jiang S, Shen M and Yang Y: The roles of liver X receptor α in inflammation and inflammation-associated diseases. J Cell Physiol 36: 4807-4828, 2021.
35. Hanashiro J, Muraosa Y, Toyotome T, Hirose K, Watanabe A and Kamei K: Schizophyllum commune induces IL-17-mediated neutrophilic airway inflammation in OVA-induced asthma model mice. Sci Rep 9: 19321, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.